Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pregabalin naproxencarbil
- Development stage
- Phase 3
- Lead developer
- Xgene Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pregabalin naproxencarbil (NG1706, XG005) is an oral, non-opioid, small-molecule dual-acting prodrug conjugate of the NSAID naproxen and the gabapentinoid pregabalin. Originally developed by Xgene Pharmaceutical and licensed to NeuroGen Pharma in Greater China, the drug is designed to treat both inflammatory and neuropathic pain. Upon absorption, it is metabolized into naproxen and pregabalin, which simultaneously inhibit cyclooxygenase (COX) enzymes and modulate the alpha-2/delta-1 subunit of voltage-gated calcium channels (CACNA2D1). This dual mechanism of action targets multiple pain pathways to provide broad-spectrum analgesia with improved gastrointestinal and central nervous system safety compared to traditional therapies. Pregabalin naproxencarbil has completed Phase IIb/III clinical trials for acute post-surgical pain following bunionectomy in the US and Phase IIb trials for chronic osteoarthritis pain in China.
- Other names
- PNCpregabalin naproxencarbilpregabalin naproxencarbilum
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (Voltage-gated calcium channel subunit alpha-2/delta-2)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)α2δ (Voltage-gated calcium channel alpha-2-delta subunit)
Beyond the preview
Go deeper on pregabalin naproxencarbil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pregabalin naproxencarbil.